CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient and Clinician Input

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Tagrisso (osimertinib)

Therapeutic Area: Non-small cell lung cancer

Call For Patient Input: February 24, 2021

Patient Input Closed: April 16, 2021

TBC (inclisiran)

Therapeutic Area: Primary hypercholesterolemia

Call For Patient Input: February 17, 2021

Patient Input Closed: April 9, 2021

Onureg (azacitidine )

Therapeutic Area: Acute myeloid leukemia

Call For Patient Input: January 29, 2021

Patient Input Closed: March 26, 2021

Xeomin (incobotulinumtoxin A )

Therapeutic Area: Chronic sialorrhea associated with neurological disorders

Call For Patient Input: January 28, 2021

Patient Input Closed: March 19, 2021

Givlaari (givosiran )

Therapeutic Area: Acute hepatic porphyria (AHP) in adults

Call For Patient Input: January 25, 2021

Patient Input Closed: March 19, 2021

Evenity (romosozumab)

Therapeutic Area: Osteoporosis, postmenopausal women

Call For Patient Input: January 4, 2021

Patient Input Closed: February 26, 2021